Conservative treatment of chronic lower limb ischemia in ambulatory practice

Close metadata

Recommended articles:

The role of medical check-up in the detection of colon diseases. Russian Journal of Preventive Medicine. 2023;(11):34-38

Digital technologies in corporate health promotion programs: international and domestic experience. Russian Journal of Preventive Medicine. 2023;(11):116-121

Prospects for predicting preterm labor. Russian Bulletin of Obstetrician-Gynecologist. 2023;(6-2):127-134

Assessment of eating habits, psycho-emotional state, quality of life and risk factors for the development of gestational diabetes mellitus in women with threatened late miscarriage. Russian Bulletin of Obstetrician-Gynecologist. 2023;(6-2):155-161

Bilirubin is a promising target for metabolic and atherosclerotic cardiovascular diseases. Russian Journal of Preventive Medicine. 2024;(1):121-127

Management of patients with nonspecific neck pain. Russian Journal of Pain. 2024;(1):40-46

Prevalence and risk factors of non-suicidal self-injury behavior. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(2):13-19

Effectiveness of body weight control using remote digital technologies in various organizational models of primary health care. Medical Technologies. Assessment and Choice. 2024;(1):26-36

Ischemic stroke in men 18—50 years of age. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3-2):5-11

Prevalence of cardiovascular diseases risk factors in Magadan schoolchildren. Russian Journal of Preventive Medicine. 2024;(3):39-44

Peripheral artery disease is still one of the most important surgical problems. General surgeons treat the majority of patients with chronic lower limb ischemia due to the lack of specialized surgical care. Current methods for risk factors adjustment, exercise therapy and the most common drugs for intermittent claudication management are reviewed in the article. The effect of these medicines on subjective (pain-free walking distance, maximal walking distance, etc.) and objective (ankle-brachial index) parameters and the incidence of complications are analyzed.

Keywords:

chronic lower limb ischemia

intermittent claudication

conservative treatment

risk factors

exercise therapy

pentoxifylline

cilostazol

aspirin

clopidogrel

naftidrofuryl

prostaglandins

propionyl-L-carnitine

actovegin

sulodexide

VEGF165

neovasculgen

Authors:

Shabunin A.V.

S.P. Botkin City Clinical Hospital, Moscow, Russia;
Russian Medical Academy of Continuous Professional Education, Ministry of Health of the Russian Federation, Moscow, Russia

Matveev D.V.

Kafedra gospital'noĭ khirurgii GBOU DPO RMAPO Minzdrava Rossii

Kuznetsov M.R.

Pirogov Russian National Research Medical University, Moscow, Russia

Matveev A.D.

Russian Medical Academy of Postgraduate Education, Moscow, Russia

List of references:

Aboyans V, Ricco JB, Marie-Louise EL, Bjorck M, Brodmann M, Cohnert T, Collet JP, Czerny M, De Carlo M, Debus S, Espinola-Klein C, Kahan T, Kownator S , Mazzolai LA, Ross Naylor, Roffi M, Rother J, Sprynger M, Tendera M, Tepe G, Venermo M, Vlachopoulos C, Desormais I. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). European Heart Journal. 2018 March;39(9):763-816. https://doi.org/10.1016/j.rec.2017.12.014
Fatmata B, Steve S. Bhimji. Peripheral Arterial Disease Upstate Medical University Last Update: February 7, 2017. https://www.ncbi.nlm.nih.gov/books/NBK430745/
Willigendael EM, Teijink JA, Bartelink ML, Peters RJ, Büller HR, Prins MH. Smoking and the patency of lower extremity bypass grafts: a metaanalysis. J Vasc Surg. 2005;42:67-74. https://doi.org/10.1016/j.jvs.2005.03.024
Aiello FA, Khan AA, Meltzer AJ, Gallagher KA, McKinsey JF, Schneider DB. Statin therapy is associated with superior clinical outcomes after endovascular treatment of critical limb ischemia. J Vasc Surg. 2012;55:371-379. https://doi.org/10.1016/j.jvs.2011.08.044
Aung PP, Maxwell HG, Jepson RG, Price JF, Leng GC. Lipid-lowering for peripheral arterial disease of the lower limb. Cochrane Database Syst Rev. 2007;4. https://doi.org/10.1002/14651858.CD000123.pub2
Momsen AH, Jensen MB, Norager CB, Madsen MR, Vestersgaard-Andersen T, Lindholt JS. Drug therapy for improving walking distance in intermittent claudication: a systematic review and metaanalysis of robust randomised controlled studies. Eur J Vasc Endovasc Surg. 2009;38:463-474. https://doi.org/10.1016/j.ejvs.2009.06.002
Anthenelli RM, Benowitz NL, West R, St Aubin L, McRae T, Lawrence D, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet. 2016;387:2507-2520. https://doi.org/10.1016/S0140-6736(16)30272-0
Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Porriere MA, Drachman DE, et al. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease. Circulation. 2017;135:e726-e779. https://doi.org/10.1161/CIR.0000000000000471
Dias RM, Forjaz CL, de M, Cucato GG, Costa LAR, Câmara LC, Wolosker N, et al. Obesity decreases time to claudication and delays post-exercise hemodynamic recovery in elderly peripheral arterial disease patients. Gerontology. 2009;55:21-26. https://doi.org/10.1159/000155219
Mannarino E, Pasqualini L, Innocente S, Scricciolo V, Rignanese A, Ciuffetti G. Physical training and antiplatelet treatment in stage II peripheral arterial occlusive disease: alone or combined? Angiology. 1991;42(7):513-521. https://doi.org/10.1177/000331979104200701
Cohen EA, Creager MA, Easton JD, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Fabry-Ribaudo L, Hu T, Topol EJ, Fox KA. Patients with prior myocardial infarction, stroke, or symptomatic peri- pheral arterial disease in the CHARISMAtrial. J Am Coll Cardiol. 2007;49(19):1982-1988. https://doi.org/10.1016/j.jacc.2007.03.025
Hiatt WR, Fowkes FG, Heizer G, Berger JS, Baumgartner I, Held P, Katona BG, Mahaffey KW, Norgren L, Jones WS, Blomster J, Millegard M, Reist C, Patel MR. Ticagrelor versus clopidogrel in symptomatic peripheral artery disease. N Engl J Med. 2017;376:32-40. https://doi.org/10.1056/NEJMoa1611688
Whayne TF. A review of the role of anticoagulation in the treatment of peripheral arterial disease. Int J Angiol. 2012 Dec;21(4):187-194. https://doi.org/10.1055/s-0032-1330232
Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: Management of asymptomatic disease and claudication. J Vasc Surg. 2015 Mar;61(3 Suppl):54S-73S. https://doi.org/10.1016/j.jvs.2014.12.007119
Salhiyyah K, Forster R, Senanayake E, Abdel-Hadi M, Booth A, Michaels JA. Pentoxifylline for intermittent claudication (review). Cochrane Database Syst Rev. 2015 Sep 29;9:CD005262. https://doi.org/10.1002/14651858.CD005262.pub3
Stewart AH, Lamont PM. Exercise training for claudication. Surgeon. 2007 Oct;5(5):291-299. https://doi.org/10.1016/S1479-666X(07)80028-X
Creager MA, Pande RL and Hiatt WA. A randomized trial of iloprost in patients with intermittent claudication. Vascular Surgery. 2008. https://doi.org/10.1177/1358863x07084910
Schellong S, Baron Von Bilderling P, Grus JD, Lawall H, Grieger F, Ney U, et al. Intravenous alprostadil treatment compared to oral pentoxifylline treatment in outpatients with intermittent claudication: results of a clinical study. Vasa Journal of Vascular Diseases. 2012;41:78. https://doi.org/10.1024/0301-1526/a000639
Chacon-Quevedo A, Eguaras MG, Calleja F, Garcia MA, Roman M, Casares J, et al. Comparative evaluation of pentoxifylline, buflomedil, and nifedipine in the treatmentof intermittent claudication of the lower limbs. Angiology. 1994;45(7):647-653. https://doi.org/10.1177/000331979404500708
Sallustio F, Rotondo F, Di Legge S, Stanzione P. Cilostazol in the management of atherosclerosis. Current Vascular Pharmacology. 2010;8(3):363-372. https://doi.org/10.2174/157016110791112331
Chapman TM, Goa KL. Cilostazol: a review of its use in intermittent claudication. American Journal of Cardiovascular Drugs. 2003;3(2):117-138. https://doi.org/10.2165/00129784-200303020-00006
Dawson DL. Comparative effects of cilostazol and other therapies for intermittent claudication. American Journal of Cardiology. 2001;87(12A):19D-27D. https://doi.org/10.1016/S0002-9149(01)01673-3
Strandness DEJr, Dalman RL, Panian S, Rendell MS, Comp PC, Zhang P, et al. Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study. Vascular and Endovascular Surgery. 2002;36(2):83-91. https://doi.org/10.1177/153857440203600202
Dawson DL, Cutler BS, Meissner MH, Strandness DE Jr. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation. 1998;98(7):678-686. https://doi.org/10.1161/01.CIR.98.7.678
Dawson DL, Cutler BS, Hiatt WR, Hobson RW. 2nd, Martin JD, Bortey EB, et al. A comparison of cilastazol and pentoxifylline for treating intermittent claudication. American Journal of Medicine. 2000;109(7):523-530. https://doi.org/10.1016/S0002-9343(00)00569-6
Elam MB, Heckman J, Crouse JR, Hunninghake DB, Herd JA, Davidson M, et al. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arteriosclerosis, Thrombosis, and Vascular Biology. 1998;18(12):1942-1947. https://doi.org/10.1161/01.ATV.18.12.1942
Money SR, Herd JA, Isaacsohn JL, Davidson M, Cutler B, Heckman J, et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheralvascular disease. Journal of Vascular Surgery. 1998;27(2):267-274. https://doi.org/10.1016/j.ejvs.2009.06.002
Otsuka 21-95-201. A randomised double-blind study of the safety and efficacy of two different doses of cilostazol versus placebo in patients with intermittent claudication secondary to peripheral vascular disease. Accessed May 2014. www.accessdata.fda.gov/drugsatfda˙docs/nda/99/20863.cfm
Dawson DL, Cutler BS, Hiatt WR, Hobson RW. 2nd, Martin JD, Bortey EB, Forbes WP, Strandness DEJr. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med. 2000 Nov;109(7):523-530. https://doi.org/10.1016/S0002-9343(00)00569-6
Lee TM, Su SF, Hwang JJ, Tseng CD, Chen MF, Lee YT, et al. Differential lipogenic effects of cilostazol and pentoxifylline in patients with intermittent claudication: potential role for interleukin-6. Atherosclerosis 2001;158(2):471-476. https://doi.org/10.1016/S0021-9150(01)00457-9
Kieffer E, Bahnini A, Mouren X, Gamand S. A new study demonstrates the efficacy of naftidrofuryl in the treatment of intermittent claudication. Findings of the Naftidrofuryl. Clinical Ischemia Study (NCIS). Int Angiol. 2001;20:58-65.
Adhoute G, Bacourt F, Barral M, Cardon JM, Chevalier JM, Cuny A, et al. Naftidrofuryl in chronic arterial disease. Results of a six month controlled multicenter study using Naftidrofuryl tablets 200 mg. Angiology. 1986;37:160-167. https://doi.org/10.1177/000331978603700304
Stevens JW, Simpson E, Harnan S, Squires H, Meng Y, Thomas S, Michaels J and Stansby G. Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication. Br J Surg. 2012 Dec;99(12):1630-8. https://doi.org/10.1002/bjs.8895
Luo T, Li J, Li L, Yang B, Liu C, Zheng Q, Jin B, Chen Z, Li K, Zhang X, Zhang J. A study on the efficacy and safety assessment of propionyl-L-carnitine tablets in treatment of intermittent claudication. Thromb Res. 2013 Oct;132(4):427-432. https://doi.org/10.1016/j.thromres.2013.08.005
Shilov AM, Knyazeva LV. Pleiotropic Effects and Cardioprotective Action of Actovegin in Patients with Coronary Heart Disease. The Journal of General Medicine. 2012;4:64-73. (In Russ.) https://cyberleninka.ru/article/n/pleyotropnye-effekty-aktovegina-i-ego-kardioprotektivnoe-deystvie-u-bolnyh-s-ishemicheskoy-boleznyu-serdtsa
Machicao F, Muresanu DF, Hundsberger H, et al. Pleiotropic neuroprotective and metabolic effects of Actovegin’s mode of action. J Neurol Sci. 2012 Nov 15;322(1-2):222-227. https://doi.org/10.1016/j.jns.2012.07.069
Buchmayer F, Pleiner J, Elmlinger MW, et al. Actovegin: a biological drug for more than 5 decades. Pharmateka. 2012;6:20-27. (In Russ.) https://doi.org/10.1007/s10354-011-0865-y
Ostroumova OD, Bobrova LS. Actovegin capabilities in increasing cognitive functions aong patients with vascular deceases of brain. Atmoshpere. Neural deseases. 2006;3:28-32. (In Russ.) https://cyberleninka.ru/article/n/vozmozhnosti-aktovegina-v-uluchshenii-kognitivnyh-funktsiy-u-patsientov-s-sosudistymi-zabolevaniyami-golovnogo-mozga
Giarola P. Effects of blood extract on plasma lipids, blood coagulation, fibrinolysis, and platelet aggregation in experimental hypercholesterolemia of rabbits. Arzneim-Forsch. 1974;24:925-928.
Fomin AA, Pershakov DR. Actovegin in treatment of critical limb ischemia. Khirurgiia. 2015;8:54-57. (In Russ.) https://doi.org/10.17116/hirurgia2015854-57
Gaddi A, et al. Metaanalysis of some results of clinical trials on sulodexide therapy in peripheral occlusive arterial disease. The journal of international medical research. 1996;24:389-406. https://doi.org/10.1177/030006059602400501
Ouma GO, Jonas RA, Usman MH, Mohler ER III. Targets and delivery methods for therapeutic angiogenesis in peripheral artery disease. Vascular Meditsine. 2012;17(3):174-192. https://doi.org/10.1177/1358863X12438270
Kitsis RN, Mann DL. Apoptosis and the heart: a decade of progress. J Mol Cell Cardiol. 2005;38:1-2. https://doi.org/10.1016/j.yjmcc.2004.11.008
Lederman RJ, Tenaglia AN, Anderson RD, Hermiller JB, Rocha-Singh K, Mendelsohn FO, et al. Design of the therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (TRAFFIC) trial. American Journal of Cardiology. 2001;88(2):192-195. https://doi.org/10.1016/S0002-9149(01)01622-8
Rajagopalan S, Mohler III E, Lederman RJ, Saucedo J, Mendelsohn FO, Olin J, et al. Regional angiogenesis with vascular endothelial growth factor (VEGF) in peripheral arterial disease: design of the RAVE trial. American Heart Journal. 2003;145(6):1114-1118. https://doi.org/10.1016/S0002-8703(03)00102-9
Deev R, Bozo I, Mzhavanadze N, Voronov D, Gavrilenko A, Chervyakov Y, et al. pCMV-vegf165 intramuscular gene transfer is an effective method of treatment for patients with chronic lower limb ischemia. Journal of Cardiovascular Pharmacology and Therapeutics. 2015;20(5):473-482. https://doi.org/10.1177/1074248415574336
Lazarous DF, Unger EF, Epstein SE, Stine A, Arevalo JL, Chew EY, et al. Basic fibroblast growth factor in patients with intermittent claudication: results of a phase I trial. Journal of the American College of Cardiology. 2000;36(4):1239-1244. https://doi.org/10.1016/S0735-1097(00)00882-2
Cooper LTJr, Hiatt WR, Creager MA, Regensteiner JG, Casscells, Isner W, et al. Proteinuria in a placebo-controlled study of basic fibroblast growth factor for intermittent claudication. Vascular Meditsine. 2001;6(4):235-239. https://doi.org/10.1177/1358836x0100600406
Lederman RJ, Mendelsohn FO, Anderson RD, Saucedo JF, Tenaglia AN, Hermiller JB, et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet. 2002;359(9323):2053-2058. https://doi.org/10.1016/S0140-6736(02)08937-7
Kibbe MR, Hirsch AT, Mendelsohn FO, Davies MG, Pham H, Saucedo J, et al. Safety and efficacy of plasmid DNA expressing two isoforms of hepatocyte growth factor in patients with critical limb ischemia. Gene Therapy. 2016;23:306-312, 399 (corrigendum). https://doi.org/10.1038/gt.2016.9
Matyas L, Schulte KL, Dormandy JA, Norgren L, Sowade O, Grotzbach G, et al. Arteriogenic gene therapy in patients with unreconstructable critical limb ischemia: a randomized, placebo-controlled clinical trial of adenovirus 5-delivered fibroblast growth factor-4. Human Gene Therapy. 2005;16(10):1202-1211. https://doi.org/10.1089/hum.2005.16.1202
Muona K, Mäkinen K, Hedman M, Manninen H, Yla S. 10-year safety follow-up in patients with local VEGF gene transfer to ischemic lower limb. Herttuala Gene Therapy. 2012;19:392-395. https://doi.org/10.1038/gt.2011.109
Gorenoi V, Brehm MU, Koch A, Hagen A Growth factors for angiogenesis in peripheral arterial disease (review). Cochrane Database Syst Rev. 2017 Jun 8;6:CD011741. https://doi.org/10.1002/14651858.CD011741.pub2
Chervyakov YuV, Staroverov IN, Vlasenko ON, Bozo IYa, Isaev AA, Deev RV. Five-year results of treating patients with chronic lower limb ischaemia by means of gene engineering. Angiol Sosud Khir. 2016;22(4):38-43. (In Russ.)

Close metadata